Cellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Cellectis Trading Up 12.0 %

Shares of Cellectis stock opened at $3.35 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.50 and a quick ratio of 1.50. Cellectis has a 1 year low of $0.96 and a 1 year high of $3.77. The firm has a market cap of $186.19 million, a PE ratio of -1.95 and a beta of 3.08. The company has a 50 day simple moving average of $2.62 and a two-hundred day simple moving average of $2.72.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter. The company had revenue of $1.99 million for the quarter. Cellectis had a negative return on equity of 99.88% and a negative net margin of 1,087.66%. Analysts expect that Cellectis will post -1.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. boosted its position in Cellectis S.A. (NASDAQ:CLLS) by 6.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 424,533 shares of the biotechnology company’s stock after buying an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned approximately 0.76% of Cellectis worth $1,125,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.